Cavion starts enrolment in Phase II trial of CX-8998 for essential tremor

US-based biotechnology firm Cavion has started patient enrolment in a Phase II clinical trial (T-CALM Study) of CX-8998 to treat essential tremor (ET).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news